JP2005535285A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005535285A5 JP2005535285A5 JP2003564220A JP2003564220A JP2005535285A5 JP 2005535285 A5 JP2005535285 A5 JP 2005535285A5 JP 2003564220 A JP2003564220 A JP 2003564220A JP 2003564220 A JP2003564220 A JP 2003564220A JP 2005535285 A5 JP2005535285 A5 JP 2005535285A5
- Authority
- JP
- Japan
- Prior art keywords
- genes
- expression level
- liver
- 5www
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims 53
- 238000000034 method Methods 0.000 claims 48
- 230000014509 gene expression Effects 0.000 claims 46
- 239000000523 sample Substances 0.000 claims 27
- 210000005228 liver tissue Anatomy 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 12
- 210000003494 hepatocyte Anatomy 0.000 claims 12
- 239000007787 solid Substances 0.000 claims 12
- 231100000765 toxin Toxicity 0.000 claims 10
- 239000003053 toxin Substances 0.000 claims 10
- 108700012359 toxins Proteins 0.000 claims 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 8
- 210000004185 liver Anatomy 0.000 claims 8
- UMFJAHHVKNCGLG-UHFFFAOYSA-N n-Nitrosodimethylamine Chemical compound CN(C)N=O UMFJAHHVKNCGLG-UHFFFAOYSA-N 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 231100000331 toxic Toxicity 0.000 claims 7
- 230000002588 toxic effect Effects 0.000 claims 7
- 238000003556 assay Methods 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 4
- CZIHNRWJTSTCEX-UHFFFAOYSA-N 2 Acetylaminofluorene Chemical compound C1=CC=C2C3=CC=C(NC(=O)C)C=C3CC2=C1 CZIHNRWJTSTCEX-UHFFFAOYSA-N 0.000 claims 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 4
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 claims 4
- 108091034117 Oligonucleotide Proteins 0.000 claims 4
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims 4
- -1 CPA Chemical compound 0.000 claims 3
- 206010019851 Hepatotoxicity Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 231100000304 hepatotoxicity Toxicity 0.000 claims 3
- 230000007686 hepatotoxicity Effects 0.000 claims 3
- 210000005229 liver cell Anatomy 0.000 claims 3
- 231100000614 poison Toxicity 0.000 claims 3
- 239000002574 poison Substances 0.000 claims 3
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims 2
- JBDOSUUXMYMWQH-UHFFFAOYSA-N 1-naphthyl isothiocyanate Chemical compound C1=CC=C2C(N=C=S)=CC=CC2=C1 JBDOSUUXMYMWQH-UHFFFAOYSA-N 0.000 claims 2
- 101150072531 10 gene Proteins 0.000 claims 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims 2
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 claims 2
- QDPMHXUWMPNTEQ-UHFFFAOYSA-N 2-amino-7-(thiophen-3-ylmethyl)-1,5-dihydropyrrolo[3,2-d]pyrimidin-4-one Chemical compound C1=2NC(N)=NC(=O)C=2NC=C1CC=1C=CSC=1 QDPMHXUWMPNTEQ-UHFFFAOYSA-N 0.000 claims 2
- UERHIZBSLAGDLU-UHFFFAOYSA-N 3-(2,3,4,5,6,7,8,8a-octahydro-1h-pyrrolo[1,2-a]pyrazine-2,5-diium-2-yl)-1-(2-chlorophenothiazin-10-yl)propan-1-one;dichloride Chemical compound Cl.Cl.C1CN2CCCC2CN1CCC(=O)N1C2=CC=CC=C2SC2=CC=C(Cl)C=C21 UERHIZBSLAGDLU-UHFFFAOYSA-N 0.000 claims 2
- 206010008635 Cholestasis Diseases 0.000 claims 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims 2
- 208000004930 Fatty Liver Diseases 0.000 claims 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims 2
- 206010020880 Hypertrophy Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 2
- 229960004150 aciclovir Drugs 0.000 claims 2
- 230000003321 amplification Effects 0.000 claims 2
- 229960000997 bicalutamide Drugs 0.000 claims 2
- 230000004640 cellular pathway Effects 0.000 claims 2
- 231100000359 cholestasis Toxicity 0.000 claims 2
- 230000007870 cholestasis Effects 0.000 claims 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims 2
- 229960001214 clofibrate Drugs 0.000 claims 2
- 229960001338 colchicine Drugs 0.000 claims 2
- 229960001259 diclofenac Drugs 0.000 claims 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims 2
- 229960000616 diflunisal Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 229960003627 gemfibrozil Drugs 0.000 claims 2
- 206010019692 hepatic necrosis Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 231100000784 hepatotoxin Toxicity 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 2
- 229960000905 indomethacin Drugs 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 231100000252 nontoxic Toxicity 0.000 claims 2
- 230000003000 nontoxic effect Effects 0.000 claims 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims 2
- 229960005489 paracetamol Drugs 0.000 claims 2
- 210000002824 peroxisome Anatomy 0.000 claims 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims 2
- 229960002695 phenobarbital Drugs 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 2
- 229960001685 tacrine Drugs 0.000 claims 2
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 229960000604 valproic acid Drugs 0.000 claims 2
- 235000012711 vitamin K3 Nutrition 0.000 claims 2
- 239000011652 vitamin K3 Substances 0.000 claims 2
- 229940041603 vitamin k 3 Drugs 0.000 claims 2
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 claims 2
- 229960005332 zileuton Drugs 0.000 claims 2
- 208000005623 Carcinogenesis Diseases 0.000 claims 1
- 238000000636 Northern blotting Methods 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 1
- 230000036952 cancer formation Effects 0.000 claims 1
- 230000000711 cancerogenic effect Effects 0.000 claims 1
- 231100000504 carcinogenesis Toxicity 0.000 claims 1
- 231100000315 carcinogenic Toxicity 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 230000007866 hepatic necrosis Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 231100000149 liver necrosis Toxicity 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 238000002493 microarray Methods 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 238000003753 real-time PCR Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- 230000008791 toxic response Effects 0.000 claims 1
- 239000002435 venom Substances 0.000 claims 1
- 231100000611 venom Toxicity 0.000 claims 1
- 210000001048 venom Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6008702A | 2002-01-31 | 2002-01-31 | |
| US36405502P | 2002-03-15 | 2002-03-15 | |
| US36404502P | 2002-03-15 | 2002-03-15 | |
| US43664302P | 2002-12-30 | 2002-12-30 | |
| PCT/US2003/003194 WO2003064624A2 (en) | 2002-01-31 | 2003-01-31 | Molecular hepatotoxicology modeling |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005535285A JP2005535285A (ja) | 2005-11-24 |
| JP2005535285A5 true JP2005535285A5 (cg-RX-API-DMAC7.html) | 2006-03-16 |
Family
ID=27670970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003564220A Pending JP2005535285A (ja) | 2002-01-31 | 2003-01-31 | 分子肝毒性モデリング |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070027634A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1476747A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005535285A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003214981A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2471661A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003064624A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7447594B2 (en) | 2001-07-10 | 2008-11-04 | Ocimum Biosolutions, Inc. | Molecular cardiotoxicology modeling |
| US20050071088A1 (en) * | 2001-08-13 | 2005-03-31 | Landfield Philip W | Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment |
| EP1361433A3 (en) * | 2002-04-09 | 2005-02-23 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Method for estimating therapeutic efficacy of tumor necrosis factor (TNF) |
| JP2007501617A (ja) * | 2003-08-07 | 2007-02-01 | ジーン ロジック インコーポレイテッド | 初代ラット肝細胞毒性モデリング |
| US7294704B2 (en) | 2003-08-15 | 2007-11-13 | Diadexus, Inc. | Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk |
| US8131473B1 (en) * | 2004-05-20 | 2012-03-06 | Metabolon, Inc. | Data analysis methods for locating entities of interest within large, multivariable datasets |
| KR100565698B1 (ko) * | 2004-12-29 | 2006-03-28 | 디지탈 지노믹스(주) | 급성골수성백혈병(aml), b-세포형 급성임파구성백혈병(b-all), t 세포형 급성임파구성백혈병(t-all) 진단용 마커 |
| US8048638B2 (en) * | 2005-04-01 | 2011-11-01 | University Of Florida Research Foundation, Inc. | Biomarkers of liver injury |
| AU2006232370B2 (en) * | 2005-04-01 | 2011-10-06 | Banyan Biomarkers | Biomakers of liver injury |
| US11151895B2 (en) * | 2006-08-25 | 2021-10-19 | Ronald Weitzman | Population-sample regression in the estimation of population proportions |
| US10957217B2 (en) | 2006-08-25 | 2021-03-23 | Ronald A. Weitzman | Population-sample regression in the estimation of population proportions |
| ES2665245T3 (es) | 2008-08-11 | 2018-04-25 | Banyan Biomarkers, Inc. | Proceso de detección de biomarcador y ensayo de estado neurológico |
| EP2264454A1 (en) * | 2009-06-11 | 2010-12-22 | Universiteit Maastricht | Method for screening compounds for preventing the adverse effects of reactive oxygen species on eukaryotic cells |
| US9682132B2 (en) | 2010-01-26 | 2017-06-20 | Banyan Biomarkers, Inc | Compositions and methods relating to argininosucccinate synthetase |
| JP5804629B2 (ja) * | 2011-07-29 | 2015-11-04 | 株式会社メディクローム | 遺伝子発現変動解析による化学物質の毒性評価方法 |
| US10191033B2 (en) | 2013-12-05 | 2019-01-29 | The Broad Institute, Inc. | Biomarkers for detecting pre-cachexia or cachexia and methods of treatment thereof |
| EP3389715A4 (en) | 2015-12-14 | 2019-06-12 | David K. Thomas | COMPOSITIONS AND METHODS FOR TREATING CARDIAL DYSFUNCTION |
| JP2016104032A (ja) * | 2016-02-23 | 2016-06-09 | 株式会社メディクローム | 化学物質の生体毒性の評価方法 |
| CN110366558A (zh) | 2016-10-28 | 2019-10-22 | 班扬生物标记公司 | 针对泛素c末端水解酶l1(uch-l1)和胶质纤维酸性蛋白(gfap)的抗体及相关方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU692434B2 (en) * | 1993-01-21 | 1998-06-11 | President And Fellows Of Harvard College | Methods and diagnostic kits utilizing mammalian stress promoters to determine toxicity of a compound |
| US5858659A (en) * | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US6228589B1 (en) * | 1996-10-11 | 2001-05-08 | Lynx Therapeutics, Inc. | Measurement of gene expression profiles in toxicity determination |
| CA2270527A1 (en) * | 1996-11-04 | 1998-05-14 | 3-Dimensional Pharmaceuticals, Inc. | System, method, and computer program product for the visualization and interactive processing and analysis of chemical data |
| US6165709A (en) * | 1997-02-28 | 2000-12-26 | Fred Hutchinson Cancer Research Center | Methods for drug target screening |
| US6153421A (en) * | 1997-07-18 | 2000-11-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Cloned genomes of infectious hepatitis C viruses and uses thereof |
| WO1999010536A1 (en) * | 1997-08-22 | 1999-03-04 | Yale University | A process to study changes in gene expression in granulocytic cells |
| AU1166199A (en) * | 1997-11-20 | 1999-06-15 | Smithkline Beecham Corporation | Methods for identifying the toxic/pathologic effect of environmental stimuli on gene transcription |
| AU2341999A (en) * | 1998-01-26 | 1999-08-09 | Schering Aktiengesellschaft | Gene expression methods for screening compounds |
| US6403778B1 (en) * | 1998-05-04 | 2002-06-11 | Incyte Genomics, Inc. | Toxicological response markers |
| US6132969A (en) * | 1998-06-19 | 2000-10-17 | Rosetta Inpharmatics, Inc. | Methods for testing biological network models |
| US6218122B1 (en) * | 1998-06-19 | 2001-04-17 | Rosetta Inpharmatics, Inc. | Methods of monitoring disease states and therapies using gene expression profiles |
| US6203987B1 (en) * | 1998-10-27 | 2001-03-20 | Rosetta Inpharmatics, Inc. | Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns |
| AU778844B2 (en) * | 1998-12-09 | 2004-12-23 | Vistagen, Inc. | Toxicity typing using embryoid bodies |
| WO2000046404A1 (en) * | 1999-02-05 | 2000-08-10 | Wrair Walter Reed Army Institute Of Research | Method of diagnosing of exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes |
| US6372431B1 (en) * | 1999-11-19 | 2002-04-16 | Incyte Genomics, Inc. | Mammalian toxicological response markers |
| US20010049139A1 (en) * | 2000-03-23 | 2001-12-06 | Eric Lagasse | Hepatic regeneration from hematopoietic stem cells |
| HK1054980A1 (zh) * | 2000-06-14 | 2003-12-19 | Vistagen, Inc. | 利用肝脏干细胞进行毒性分型 |
| WO2002006537A2 (en) * | 2000-07-13 | 2002-01-24 | Curagen Corporation | Methods of identifying renal protective factors |
| AU2001280889A1 (en) * | 2000-07-31 | 2002-02-13 | Gene Logic, Inc. | Molecular toxicology modeling |
| AU2002230997A1 (en) * | 2000-12-15 | 2002-06-24 | Genetics Institute, Llc | Methods and compositions for diagnosing and treating rheumatoid arthritis |
| US7993907B2 (en) * | 2001-05-08 | 2011-08-09 | Mowycal Lending, Llc | Biochips and method of screening using drug induced gene and protein expression profiling |
| AU2002316146B2 (en) * | 2001-05-15 | 2007-09-06 | Psychogenics Inc. | Systems and methods for monitoring behaviour informatics |
-
2003
- 2003-01-31 AU AU2003214981A patent/AU2003214981A1/en not_active Abandoned
- 2003-01-31 US US10/501,933 patent/US20070027634A1/en not_active Abandoned
- 2003-01-31 CA CA002471661A patent/CA2471661A1/en not_active Abandoned
- 2003-01-31 JP JP2003564220A patent/JP2005535285A/ja active Pending
- 2003-01-31 WO PCT/US2003/003194 patent/WO2003064624A2/en not_active Ceased
- 2003-01-31 EP EP03710830A patent/EP1476747A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005535285A5 (cg-RX-API-DMAC7.html) | ||
| Mazars et al. | High-resolution minisatellite-based typing as a portable approach to global analysis of Mycobacterium tuberculosis molecular epidemiology | |
| Lasken | Genomic DNA amplification by the multiple displacement amplification (MDA) method | |
| EP3285926B1 (en) | Kit and method for high throughput microbiology applications | |
| Kim et al. | High-throughput automated microfluidic sample preparation for accurate microbial genomics | |
| Honda et al. | Differential gene expression between chronic hepatitis B and C hepatic lesion | |
| Buttner et al. | Enhanced detection of surface-associated bacteria in indoor environments by quantitative PCR | |
| Spits et al. | Whole-genome multiple displacement amplification from single cells | |
| Paulino et al. | Analysis of Malassezia microbiota in healthy superficial human skin and in psoriatic lesions by multiplex real-time PCR | |
| Vernel-Pauillac et al. | Proinflammatory and Immunomodulatory Cytokine mRNA Time Course Profiles in Hamsters Infected with a Virulent Variant of Leptospirainterrogans | |
| Yu et al. | Microfluidic whole genome amplification device for single cell sequencing | |
| Geng et al. | Single-cell forensic short tandem repeat typing within microfluidic droplets | |
| Robertson et al. | New microbiology tools for public health and their implications | |
| JP2003530116A5 (cg-RX-API-DMAC7.html) | ||
| Lu et al. | Recent advances in preimplantation genetic diagnosis and screening | |
| Walker | Studying the human microbiota | |
| Lamsyah et al. | Association of PTPN22 gene functional variants with development of pulmonary tuberculosis in Moroccan population | |
| Spigelman et al. | Evolutionary changes in the genome of Mycobacterium tuberculosis and the human genome from 9000 years BP until modern times | |
| Young et al. | Microsatellite mapping of Mycobacterium leprae populations in infected humans | |
| Wei et al. | Assessing the association of leukocyte telomere length with ankylosing spondylitis and rheumatoid arthritis: a bidirectional Mendelian randomization study | |
| Weiss et al. | Sequential patterns of gene expression by bovine monocyte-derived macrophages associated with ingestion of mycobacterial organisms | |
| US10788452B2 (en) | High resolution systems, kits, apparatus, and methods for bacterial community relationship determination and other high throughput microbiology applications | |
| AU2017335897A1 (en) | High resolution systems, kits, apparatus, and methods for bacterial community relationship determination and other high throughput microbiology applications | |
| Marquis et al. | Fibrotic response as a distinguishing feature of resistance and susceptibility to pulmonary infection with Mycobacterium tuberculosis in mice | |
| JP2019531730A5 (cg-RX-API-DMAC7.html) |